MX389378B - Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. - Google Patents

Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.

Info

Publication number
MX389378B
MX389378B MX2019008331A MX2019008331A MX389378B MX 389378 B MX389378 B MX 389378B MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 389378 B MX389378 B MX 389378B
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
pharmaceutical use
janus kinase
novel amino
compounds
Prior art date
Application number
MX2019008331A
Other languages
English (en)
Other versions
MX2019008331A (es
Inventor
Andreas Ritzen
Jens Larsen
Lars Kyhn Rasmussen
Mogens Larsen
Tine Marianne Duus
Original Assignee
Aqilion Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion Ab filed Critical Aqilion Ab
Publication of MX2019008331A publication Critical patent/MX2019008331A/es
Publication of MX389378B publication Critical patent/MX389378B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de acuerdo con la fórmula (I) Ver formula. o sales, hidratos o solvatos farmacéuticamente aceptables de estos; donde R, es alquiloC1, R2 es alquilo C1, R3 es alquilo C2, R4 es hidrógeno, Rs es hidrógeno. La invención se refiere además a los compuestos para uso en terapia, a composiciones farmacéuticas que comprenden los compuestos, a los compuestos para uso en el tratamiento de enfermedades autoinmunitarias y a Intermediarios para la preparación de los compuestos.
MX2019008331A 2017-01-11 2018-01-10 Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. MX389378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
MX2019008331A MX2019008331A (es) 2020-01-14
MX389378B true MX389378B (es) 2025-03-20

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008331A MX389378B (es) 2017-01-11 2018-01-10 Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.

Country Status (26)

Country Link
US (1) US10703751B2 (es)
EP (1) EP3568396B1 (es)
JP (1) JP7009504B2 (es)
KR (1) KR102548543B1 (es)
CN (1) CN110167938B (es)
AU (1) AU2018208516B2 (es)
CA (1) CA3045567A1 (es)
CY (1) CY1123864T1 (es)
DK (1) DK3568396T3 (es)
ES (1) ES2846741T3 (es)
HR (1) HRP20210095T1 (es)
HU (1) HUE052720T2 (es)
IL (1) IL267829B (es)
LT (1) LT3568396T (es)
MX (1) MX389378B (es)
MY (1) MY195576A (es)
NZ (1) NZ754922A (es)
PL (1) PL3568396T3 (es)
PT (1) PT3568396T (es)
RS (1) RS61317B1 (es)
RU (1) RU2019125177A (es)
SI (1) SI3568396T1 (es)
TW (1) TWI760419B (es)
UA (1) UA123972C2 (es)
WO (1) WO2018130563A1 (es)
ZA (1) ZA201904190B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3818060B1 (en) * 2018-07-06 2023-02-22 LEO Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
EP4023647B1 (en) * 2019-08-30 2025-04-09 TSD Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
KR20130108543A (ko) * 2010-08-05 2013-10-04 암젠 인코포레이션 역형성 림프종 키나제를 억제하는 벤즈이미다졸 및 아자벤즈이미다졸 화합물
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
UY34615A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
AU2013337824B2 (en) 2012-11-01 2018-03-08 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
WO2014081718A1 (en) * 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
JP2017514832A (ja) 2014-04-30 2017-06-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１抑制剤を調製する方法及びその新しい形態
CN108366994B (zh) 2016-10-03 2021-10-01 杭州高光制药有限公司 新型Jak1选择性抑制剂及其用途
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Also Published As

Publication number Publication date
HRP20210095T1 (hr) 2021-03-05
RU2019125177A3 (es) 2021-05-11
US20190367512A1 (en) 2019-12-05
US10703751B2 (en) 2020-07-07
CA3045567A1 (en) 2018-07-19
RU2019125177A (ru) 2021-02-15
AU2018208516A1 (en) 2019-07-11
CY1123864T1 (el) 2022-05-27
KR20190103231A (ko) 2019-09-04
HUE052720T2 (hu) 2021-05-28
BR112019014191A2 (pt) 2020-02-11
LT3568396T (lt) 2021-02-10
AU2018208516B2 (en) 2021-07-08
DK3568396T3 (da) 2021-01-18
WO2018130563A1 (en) 2018-07-19
EP3568396B1 (en) 2020-11-11
RS61317B1 (sr) 2021-02-26
JP2020504186A (ja) 2020-02-06
PL3568396T3 (pl) 2021-05-31
NZ754922A (en) 2025-11-28
ZA201904190B (en) 2020-10-28
CN110167938B (zh) 2024-06-14
ES2846741T3 (es) 2021-07-29
JP7009504B2 (ja) 2022-01-25
SI3568396T1 (sl) 2021-04-30
PT3568396T (pt) 2021-02-09
MX2019008331A (es) 2020-01-14
KR102548543B1 (ko) 2023-06-29
UA123972C2 (uk) 2021-06-30
TW201829407A (zh) 2018-08-16
TWI760419B (zh) 2022-04-11
EP3568396A1 (en) 2019-11-20
CN110167938A (zh) 2019-08-23
MY195576A (en) 2023-02-02
IL267829A (en) 2019-09-26
IL267829B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112016016844A2 (pt) Compostos heterocíclicos
CR20120628A (es) Morfolinopirimidinas y su uso en terapia
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
CL2022003646A1 (es) Derivados de amidopirimidona
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2024009161A (es) Compuestos de pirrolidina.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
CL2021000282A1 (es) Inhibidores de ckd8/19
MX2025013985A (es) Inhibidores de prmt5
DOP2022000075A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4